利伐沙班治疗静脉血栓效果好吗？

It is an oral anticoagulant used for:

1. Adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE).

2. Treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

3. Adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Is rivaroxaban effective in treating venous thrombosis?

Analyze the clinical value of rivaroxaban in the treatment of deep vein thrombosis of lower limbs after general surgery. A total of 72 patients who underwent general surgery were selected as research subjects and divided into an observation group and a control group according to different medications, with 36 cases in each group. All patients underwent general surgical treatment and symptomatic treatment. The control group was given intravenous infusion of Salvia miltiorrhiza injection after surgery, while the observation group was given oral rivaroxaban tablets after surgery. The efficacy of the two drugs in preventing postoperative deep vein thrombosis of the lower limbs was compared.

Results: The incidence rates of lower limb deep vein thrombosis in the two groups of patients were 8.33% and 11.11% respectively, with no statistically significant difference (P>0.05); in the comparison of coagulation indicators (PT, APTT, Fgb) between the two groups of patients, there was no statistically significant difference (P>0.05), and the two drugs were equally effective.

Conclusion: Compared with Salvia miltiorrhiza injection, Rivaroxaban Tablets can effectively prevent the formation of deep vein thrombosis of lower limbs after general surgery, and has good safety, so it is worthy of promotion and application.

Precautions when taking rivaroxaban:

In special circumstances, such as suspected overdose, severe bleeding events, emergency surgery, thromboembolic events, or suspected poor compliance, prothrombin time (PT) or anti-factor Xa activity needs to be determined.

The anticoagulant effect is predictable, there is no accumulation after multiple administrations, and there are few interactions with drugs and food, so routine coagulation monitoring is not required.